Capivasertib in Combination with Faslodex Granted Priority Review in the US for Patients with Advanced HR-Positive Breast Cancer

3 years ago

by David Miller

951 Views

Written by David Miller

12 June 2023 — AstraZeneca’s New Drug Application (NDA) for capivasertib in combination with Faslodex (fulvestrant) has been accepted and granted Priority Review in the US for the treatment of adult patients with hormone receptor…Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

View all posts

[mwai_chat window="true" fullscreen="true"]

You may also like

About the author

David Miller